Multiple Myeloma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys)

March 07 19:00 2023
Multiple Myeloma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys)
The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Multiple Myeloma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Insights

 

Multiple Myeloma Overview

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein),Mspike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system

 

Some of the key facts of the Multiple Myeloma Market Report: 

  • The Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States
  • In the year 2020, the total incident case of Multiple Myeloma was 70,577 cases in the 7MM and theUnited States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period
  • Among the EU-5 countries, the highest number of cases of Multiple myeloma were in Germany, i.e.7,600 cases in the year 2020
  • Key Multiple Myeloma Companies: Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Jansesn Research and Development, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen, and others
  • Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamabs, REGN5458, Iberdomide, Descartes-11, and others
  • A bispecific antibody called NB-383B that engages CD3 T-cells and BCMA is being tested on patients with multiple myeloma who have relapsed or are resistant to at least three courses of therapy. TeneoOne is working on TNB-383B through Phase 1. The sole authority to buy TeneoOne and oversee the further international development and commercialization of TNB-383B belongs to AbbVie
  • The Multiple Myeloma epidemiology based on gender analyzed that males are affected more, in case of Multiple Myeloma (MM) as compared to females

 

Get a Free sample for the Multiple Myeloma Market Report – 

https://www.delveinsight.com/sample-request/multiple-myeloma-market

 

Key benefits of the Multiple Myeloma Market report:

  1. Multiple Myeloma market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma Epidemiology and Multiple Myeloma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Multiple Myeloma market report provides insights on the current and emerging therapies.
  3. Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Multiple Myeloma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Multiple Myeloma market.

 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiological Insights 

 

Multiple Myeloma Market  

The dynamics of the Multiple Myeloma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Multiple Myeloma
  • Prevalent Cases of Multiple Myeloma by severity
  • Gender-specific Prevalence of Multiple Myeloma
  • Diagnosed Cases of Episodic and Chronic Multiple Myeloma

 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma market forecast 

 

Multiple Myeloma Therapies and Key Companies

  • Venetoclax: AbbVie and Roche 
  • ABBV 383: AbbVie
  • Teclistamab: Janssen Pharmaceutical
  • Talquetamab: Janssen Pharmaceuticals
  • REGN5458: Regeneron Pharmaceuticals
  • Iberdomide: Bristol-Myers Squibb/Celgene
  • Descartes-11: Cartesian Therapeutics

 

Multiple Myeloma Market Drivers

  • Increasing incidence rate of Multiple Myeloma
  • High adoption rate of newer therapies
  •  Increase in the Geriatric Population

 

Scope of the Multiple Myeloma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Multiple Myeloma Companies: Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Jansesn Research and Development, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen, and others
  • Key Multiple Myeloma Therapies: Venetoclax, ABBV 383, Teclistamab, Talquetamabs, REGN5458, Iberdomide, Descartes-11, and others
  • Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
  • Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement 

 

Multiple Myeloma Market Barriers

  • Expensive treatment options of Multiple Myeloma
  • Toxicities and adverse events of various Multiple Myeloma therapeutics

 

Table of Contents 

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma 

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2019–2032)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17.  Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Multiple Myeloma treatment, visit @ Multiple Myeloma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis

view more articles

About Article Author